First-pass extracted concept

Cas9/sgRNA ribonucleoproteins

Candidate: concept label1 source documents4 linked claims
Live refresh every 5sNext refresh in 5s

Aliases

Cas9 RNPs

Evidence Snippets

We demonstrate that MuVLPs can be loaded with diverse payloads, including EGFP, Cre and Cas9/sgRNA ribonucleoproteins (Cas9 RNPs).
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1functional outcomesupports2025Source 1DOIPubMed

Treated mice showed significantly increased exercise capacity and endurance after MuVLP-mediated Cas9 RNP treatment.

Quoted textsource-backed
As a result, the treated mice exhibit a significantly increased capacity for exercise and endurance.
Claim 2payload compatibilitysupports2025Source 1DOIPubMed

MuVLPs can be loaded with EGFP, Cre, and Cas9/sgRNA ribonucleoproteins and delivered into skeletal muscle cells via targeted membrane fusion.

Quoted textsource-backed
We demonstrate that MuVLPs can be loaded with diverse payloads, including EGFP, Cre and Cas9/sgRNA ribonucleoproteins (Cas9 RNPs), and can be delivered into skeletal muscle cells via targeted membrane fusion.
Claim 3phenotypic outcomesupports2025Source 1DOIPubMed

MuVLP-mediated Cas9 RNP treatment restored dystrophin expression in multiple skeletal muscle tissues in the DMD mouse model.

Quoted textsource-backed
This treatment restores dystrophin expression in various skeletal muscle tissues, including the diaphragm, quadriceps, tibialis anterior, gastrocnemius, and triceps.
Claim 4therapeutic applicationsupports2025Source 1DOIPubMed

Systemically administered MuVLPs carrying Cas9 RNPs enabled skeletal muscle-specific gene editing that excised a premature-terminator-containing exon in a DMD mouse model.

Quoted textsource-backed
Systemic administration of MuVLPs carrying Cas9 RNPs enables skeletal muscle-specific gene editing, which excised the exon containing a premature terminator codon mutation in a mouse model for Duchenne muscular dystrophy (DMD).